ABOS - NASDAQ

Acumen Pharmaceuticals, Inc.

ABOS·NASDAQ

$2.37

+2.6%

HealthcareBiotechnology

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$143.56M

EPS-2.0000

P/E Ratio-1.05

Earnings Date08/11/2026

abos

Other Non-Cash Items

Last Annual Value

1.81M

3-Year CAGR

55%

5-Year CAGR

39%

10-Year CAGR

29%

Adjust for Inflation

Acumen Pharmaceuticals, Inc. Competitors Analysis of Other Non-Cash Items

ABOS · NASDAQ

Company	Other Non-Cash Items	CAGR 3Y	CAGR 5Y	CAGR 10Y
Acumen Pharmaceuticals, Inc. NASDAQ:ABOS	1.81M	N/A	-53.3%	N/A
Seer, Inc. NASDAQ:SEER	7.07M	N/A	47.7%	N/A
Actuate Therapeutics Inc NASDAQ:ACTU	20.25K	-45.3%	N/A	N/A
C4 Therapeutics, Inc. NASDAQ:CCCC	14.52M	61.0%	46.8%	N/A
PepGen Inc. NASDAQ:PEPG	-1.51M	N/A	N/A	N/A
Instil Bio, Inc. NASDAQ:TIL	26.09M	-24.3%	110.2%	N/A
Tevogen Bio Holdings Inc. NASDAQ:TVGN	-39.43M	N/A	N/A	N/A
Agenus Inc. NASDAQ:AGEN	15.89M	N/A	-6.5%	-1.5%
VistaGen Therapeutics, Inc. NASDAQ:VTGN	-389.00K	N/A	N/A	N/A
Alector, Inc. NASDAQ:ALEC	7.16M	N/A	27.8%	14.3%
Inovio Pharmaceuticals, Inc. NASDAQ:INO	-1.21M	N/A	N/A	N/A

Acumen Pharmaceuticals, Inc. Fair Value Envelope

ABOS · NASDAQ

Our analysis suggests that ABOS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.37, this represents a potential HIDDEN relative to our calculated worth for Acumen Pharmaceuticals, Inc..

HIDDEN

Intrinsic Value

Current Price: $2.37

Related Guides

Blog Categories

Continue your ABOS research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.